Hyperthermic intraperitoneal chemotherapy

  • Kristijan Skok Faculty of medicine, University of Maribor, Maribor, Slovenia http://orcid.org/0000-0002-3027-8164
  • Nina Skornšek Faculty of medicine, University of Maribor, Maribor, Slovenia
  • Marko Hočevar Faculty of medicine, University of Ljubljana, Ljubljana, Slovenia
  • Pavel Skok Faculty of medicine, University of Maribor, Maribor, Slovenia
Keywords: hyperthermic intraperitoneal chemotherapy, cytoreductive surgery, colorectal cancer, peritoneal carcinosis, metastases

Abstract

In the past, patients with peritoneal metastases have been treated only with palliative therapy. Their state was deemed to be incurable. The median survival time was approximately two months. The therapeutic approach started to change in the nineties. Some researchers were of the opinion that peritoneal metastases were, in certain cases, only a locoregional disease and consequently, the patient could not only be treated, but cured. One of the main supporters of this theory and new treatment approach was Paul Sugarbaker. The proposed treatment consisted of cytoreductive surgery in combination with intraperitoneal chemotherapy. The purpose of the surgical procedure is macroscopic elimination of the tumour and removal of its microscopic remains via intraperitoneal chemotherapy. The procedure in which we apply a heated chemotherapeutic agent is known as hyperthermic intraperitoneal chemotherapy. Heat on its own has some direct anti-tumour effects. It causes protein denaturation, lysosomal activation and increased apoptotic cell death. If the chemotherapeutic agent is heated, complex chemical reactions take place, which promote its effectiveness and increase the depth of penetration. The best results achieved by this method have been reported in colorectal carcinoma, appendiceal malignancies, ovarian carcinoma and peritoneal mesothelioma. In the paper, the authors present this complex procedure, indications, criteria of patient selection and contemporary knowledge on the effectiveness of this method of treatment for certain types of cancer.

Downloads

Download data is not yet available.

Author Biographies

Marko Hočevar, Faculty of medicine, University of Ljubljana, Ljubljana, Slovenia

Department of Surgical Oncology, University Medical Centre Ljubljana, Ljubljana

Department of Surgical Oncology, University Medical Centre Ljubljana, Ljubljana

Pavel Skok, Faculty of medicine, University of Maribor, Maribor, Slovenia

Medical research department, University Medical Centre Maribor, Maribor, Slovenia

References

DeVita VT, Lawrence TS, Rosenberg SA. Peritoneal Metastases and Peritoneal Mesothelioma. In: Deraco M, Elias DM, Glehen O, Helm CW, Sugarbaker PH, Verwaal VJ, editors. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10th ed. 2015. p. 2234. [Internet], Available from https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition

Lambert LA, Harris A. Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer? J Gastrointest Oncol. 2016 Feb;7(1):112–21. PMID:26941989

Canbay E, Yonemura Y, Brucher B, Baik SH, Sugarbaker PH. Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chin J Cancer Res. 2014 Feb;26(1):1–3. PMID:24653620

Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol. 2016 Feb;7(1):143–57. PMID:26941992

Arjona-Sánchez A, Medina-Fernández FJ, Muñoz-Casares FC, Casado-Adam A, Sánchez-Hidalgo JM, Rufián-Peña S. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol. 2014 Oct;6(10):407–12. https://doi.org/10.4251/wjgo.v6.i10.407 PMID:25320657

Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics. Cancer Invest. 2012 Mar;30(3):209–24. https://doi.org/10.3109/07357907.2012.654871 PMID:22360361

Poskus E, Strupas K, Gushchin V, Sugarbaker PH. Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery. Viszeralmedizin. 2014 Oct;30(5):353–9. https://doi.org/10.1159/000368685 PMID:26535046

Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016 Feb;7(1):29–44. PMID:26941982

Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003 Dec;22(4):465–72. https://doi.org/10.1023/A:1023791229361 PMID:12884919

Dubé P, Sideris L, Law C, Mack L, Haase E, Giacomantonio C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015 Apr;22(2):e100–12. https://doi.org/10.3747/co.22.2058 PMID:25908915

Bhatt A, Goéré D. Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol. 2016 Jun;7(2):177–87. https://doi.org/10.1007/s13193-016-0499-z PMID:27065708

Seshadri RA, Glehen O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol. 2016 Jun;7(2):198–207. https://doi.org/10.1007/s13193-016-0502-8 PMID:27065710

Hayes-Jordan A, Green H, Prieto V, Wolff JE. Unusual cases: melanomatosis and nephroblastomatosis treated with hyperthermic intraperitoneal chemotherapy. J Pediatr Surg. 2012 Apr;47(4):782–7. https://doi.org/10.1016/j.jpedsurg.2011.12.018 PMID:22498396

Cardi M, Sammartino P, Framarino ML, Biacchi D, Cortesi E, Sibio S, et al. Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases. Breast. 2013 Oct;22(5):845–9. https://doi.org/10.1016/j.breast.2013.02.020 PMID:23523180

Honore C, Goere D, Dartigues P, Burtin P, Dumont F, Elias D. Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz’s tumour) of the pancreas treated with HIPEC. Anticancer Res. 2012 Mar;32(3):1069–73. PMID:22399634

Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol. 2012 May;19(5):1410–5. https://doi.org/10.1245/s10434-012-2240-7 PMID:22302269

Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013 Jun;79(6):620–4. PMID:23711273

Beeharry MK, Liu WT, Yao XX, Yan M, Zhu ZG. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol. 2016 Oct;1:77. https://doi.org/10.21037/tgh.2016.08.05 PMID:28138643

H. Sugarbaker P. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: H. Sugarbaker P, ed. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Woodbury: Cine-Med Publishing; 2012. p. 57–78.

Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al.; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010 Dec;116(24):5608–18. https://doi.org/10.1002/cncr.25356 PMID:20737573

Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014 Jan;50(2):332–40. https://doi.org/10.1016/j.ejca.2013.09.024 PMID:24157254

Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016 Feb;7(1):99–111. PMID:26941988

Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995 Jan;221(1):29–42. https://doi.org/10.1097/00000658-199501000-00004 PMID:7826158

Ceelen WP, Påhlman L, Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res. 2007;134:195–214. PMID:17633055

Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003 Jul;12(3):689–701. https://doi.org/10.1016/S1055-3207(03)00029-2 PMID:14567025

Benoit L, Cheynel N, Ortega-Deballon P, Giacomo G Di, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. Springer; 2008 Feb 10;15(2):542–6. https://doi.org/10.1245/s10434-007-9635-x.

Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World J Gastroenterol. 2016 Sep;22(34):7692–707. https://doi.org/10.3748/wjg.v22.i34.7692 PMID:27678351

Bhatt A, Glehen O. The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. Indian J Surg Oncol. 2016 Jun;7(2):188–97. https://doi.org/10.1007/s13193-016-0501-9 PMID:27065709

Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol. 2006 Aug;32(6):597–601. https://doi.org/10.1016/j.ejso.2006.03.002 PMID:16617003

Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005 Feb;2(1):3. https://doi.org/10.1186/1477-7800-2-3 PMID:15701175

Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. BioMed Res Int. 2014;2014:782890. https://doi.org/10.1155/2014/782890 PMID:24783222

Sammartino P, Sibio S, Biacchi D, Cardi M, Accarpio F, Mingazzini P, et al. Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585. https://doi.org/10.1155/2012/141585 PMID:22645605

Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, et al. Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol. 2016 Jan;8(1):67–82. https://doi.org/10.4251/wjgo.v8.i1.67 PMID:26798438

Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008 Feb;34(2):196–201. https://doi.org/10.1016/j.ejso.2007.04.002 PMID:17524597

Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007 May;18(5):945–9. https://doi.org/10.1093/annonc/mdl499 PMID:17298959

Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009 Sep;100(4):331–4. https://doi.org/10.1002/jso.21321 PMID:19697441

Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012 May;19(5):1379–85. https://doi.org/10.1245/s10434-012-2238-1 PMID:22302267

Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–80. PMID:8960339

Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005 Feb;92(2):153–8. https://doi.org/10.1002/bjs.4862 PMID:15685704

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012 Jul;30(20):2449–56. https://doi.org/10.1200/JCO.2011.39.7166 PMID:22614976

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374–403. https://doi.org/10.1016/j.ejca.2012.12.027 PMID:23485231

Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015 May;15(1):428. https://doi.org/10.1186/s12885-015-1430-7 PMID:26003804

Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. Tianjing China. Chinese Anti-Cancer Association. 2016 Mar;13(1):120–35.

März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep. Oxford University Press; 2015 Nov 30;3(4):298–302. https://doi.org/10.1093/gastro/gov044.

Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003 Oct;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187 PMID:14551293

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008 Sep;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2 PMID:18521686

Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan;28(1):63–8. https://doi.org/10.1200/JCO.2009.23.9285 PMID:19917863

Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004 Aug;22(16):3284–92. https://doi.org/10.1200/JCO.2004.10.012 PMID:15310771

Park DG. Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy a Safe and Effective Procedure for Treating Patients With a Peritoneal Surface Malignancy? Ann Coloproctol. 2017 Feb;33(1):3–4. https://doi.org/10.3393/ac.2017.33.1.3 PMID:28289655

Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016 Jan;22(3):1114–30. https://doi.org/10.3748/wjg.v22.i3.1114 PMID:26811651

Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al.; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370–7. https://doi.org/10.1245/s10434-010-1039-7 PMID:20336386

Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275–84. https://doi.org/10.1002/jso.23633 PMID:25042700

Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. Baishideng Publishing Group Co. Limited. 2010 Feb;2(2):85–97.

Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016 Jun;93(11):937–44. PMID:27281838

Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol. 2016 Jun;23(3):e266–75. https://doi.org/10.3747/co.23.2831 PMID:27330364

Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014 Apr;80(4):348–52. PMID:24887664

Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009 Dec;27(36):6237–42. https://doi.org/10.1200/JCO.2009.23.9640 PMID:19917862

Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, et al.; Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011 May;117(9):1855–63. https://doi.org/10.1002/cncr.25640 PMID:21509762

Cotte E, Passot G, Gilly FN, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. Baishideng Publishing Group Co. Limited. 2010 Jan;2(1):31–5.

Published
2019-03-04
How to Cite
1.
Skok K, Skornšek N, Hočevar M, Skok P. Hyperthermic intraperitoneal chemotherapy. ZdravVestn [Internet]. 4Mar.2019 [cited 22Sep.2019];88(1-2):21-8. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/2836